Alnylam Pharmaceuticals
ALNY
#622
Rank
โ‚ฌ30.54 B
Marketcap
236,80ย โ‚ฌ
Share price
2.75%
Change (1 day)
43.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚ฌ1.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚ฌ1.25 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ1.18 B-4.06%
2022-12-31โ‚ฌ1.23 B39.73%
2021-12-31โ‚ฌ0.88 B107.88%
2020-12-31โ‚ฌ0.42 B56.24%
2019-12-31โ‚ฌ0.27 B934.23%
2018-12-31โ‚ฌ26.22 M4.88%
2017-12-31โ‚ฌ25 M-82.47%
2016-12-31โ‚ฌ0.14 B
2007-12-31โ‚ฌ4.62 M-33.15%
2006-12-31โ‚ฌ6.92 M10.91%
2005-12-31โ‚ฌ6.24 M17.6%
2004-12-31โ‚ฌ5.3 M259.52%
2003-12-31โ‚ฌ1.47 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚ฌ0.49 B-60.78%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ2.60 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.34 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.49 B-60.65%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.45 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ31.02 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ24.56 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ18.59 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel